A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 732-739

  Izhak, Liat ^a   Wildbaum, Gizi ^a   Zohar, Yaniv ^a   Anunu, Rachel ^a   Klapper, Leah ^b   Elkeles, Adi ^b   Seagal, Jane ^a   Yefenof, Eitan ^c   Ayalon Soffer, Michal ^b   Karin, Nathan ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BioLine Innovations Jerusalem   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; E3 IGG; G PROTEIN COUPLED RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; CCL2 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN STRUCTURE, FUNCTION AND VARIABILITY; IMMUNOGLOBULIN VARIABLE REGION; IN VIVO STUDY; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN TARGETING; RECEPTOR BINDING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; MIGRATION INHIBITION; MOUSE MUTANT; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; CELL PROLIFERATION; CHEMOKINE CCL2; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CCR2; RECOMBINANT FUSION PROTEINS;

EID: 68949117973     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802746     Document Type: Article

References (45)

1. Rollins, B. J. 1997. Chemokines. Blood 90: 909-928.
2. Zlotnic, A., and O. Yoshei. 2000. Chemokines: a new clasification system and their role in immunity. Immunity 12: 121-127.
3. Mackay, C. R. 2001. Chemokines: immunology's high impact factors. Nat. Immunol. 2: 95-101.
4. Proudfoot, A. E. 2002. Chemokine receptors: a multifaceted therapeutic targets. Nat. Rev. Immunol 2: 106-115.
5. Huang, D. R., J. Wang, P. Kivisakk, B. J. Rollins, and R. M. Ransohoff. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193: 713-726.
6. Kennedy, K. J., R. M. Strieter, S. L. Kunkel, N. W. Lukacs, and W. J. Karpus. 1998. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1. J. Neuroimmunol. 92: 98-108.
7. Youssef, S., G. Wildbaum, G. Maor, N. Lanir, A. Gour-Lavie, N. Grabie, and N. Karin. 1998. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161: 3870-3879.
8. Goser, S., R. Ottl, A. Brodner, T. J. Dengler, J. Torzewski, K. Egashira, N. R. Rose, H. A. Katus, and Z. Kaya. 2005. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1α in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112: 3400-3407.
9. Homey, B., A. Muller, and A. Zlotnik. 2002. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2: 175-184.
10. Garnick, M. B. 1993. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med. 118: 804-818.
11. Pienta, K. J., and P. S. Esper. 1993. Risk factors for prostate cancer. Ann. Intern. Med. 118: 793-803.
12. Loberg, R. D., L. L. Day, J. Harwood, C. Ying, L. N. St. John, R. Giles, C. K. Neeley, and K. J. Pienta. 2006. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8: 578-586.
13. Lu, Y., Z. Cai, D. L. Galson, G. Xiao, Y. Liu, D. E. George, M. F. Melhem, Z. Yao, and J. Zhang. 2006. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66: 1311-1318.
14. Loberg, R. D., C. Ying, M. Craig, L. L. Day, E. Sargent, C. Neeley, K. Wojno, L. A. Snyder, L. Yan, and K. J. Pienta. 2007. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 67: 9417-9424.
15. Caruso, D. J., A. J. Carmack, V. B. Lokeshwar, R. C. Duncan, M. S. Soloway, and B. L. Lokeshwar. 2008. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin. Cancer Res. 14: 4111-4118.
16. Waugh, D. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735-6741.
17. Akashi, T., K. Koizumi, O. Nagakawa, H. Fuse, and I. Saiki. 2006. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol. Rep. 16: 831-836.
18. Mydlo, J. H., M. I. Gerstein, C. F. Harris, and A. S. Braverman. 2003. Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology. Prostate Cancer Prostatic Dis. 6: 286-289.
19. Darash-Yahana, M., E. Pikarsky, R. Abramovitch, E. Zeira, B. Pal, R. Karplus, K. Beider, S. Avniel, S. Kasem, E. Galun, and A. Peled. 2004. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 18: 1240-1242.
20. 3 integrins. Neoplasia 8: 290-301.
21. Kukreja, P., A. B. Abdel-Mageed, D. Mondal, K. Liu, and K. C. Agrawal. 2005. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor- 1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-κB activation. Cancer Res. 65: 9891-9898.
22. Sun, Y. X., J. Wang, C. E. Shelburne, D. E. Lopatin, A. M. Chinnaiyan, M. A. Rubin, K. J. Pienta, and R. S. Taichman. 2003. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell Biochem. 89: 462-473.
23. Taichman, R. S., C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman, and L. K. McCauley. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62: 1832-1837.
24. Vaday, G. G., S. B. Hua, D. M. Peehl, M. H. Pauling, Y. H. Lin, L. Zhu, D. M. Lawrence, H. D. Foda, and S. Zucker. 2004. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin. Cancer Res. 10: 5630-5639.
25. Lu, Y., Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang. 2007. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res. 67: 3646-3653.
26. Monteclaro, F. S., and I. F. Charo. 1997. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1: receptor activation by a pseudo-tethered ligand. J. Biol. Chem. 272: 23186-23190.
27. Datta-Mannan, A., and M. J. Stone. 2004. Chemokine-binding specificity of soluble chemokine-receptor analogues: identification of interacting elements by chimera complementation. Biochemistry 43: 14602-14611.
28. Charo, I. F., S. J. Myers, A. Herman, C. Franci, A. J. Connolly, and S. R. Coughlin. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91: 2752-2756.
29. Kurihara, T., and R. Bravo. 1996. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J. Biol. Chem. 271: 11603-11607.
30. Gingrich, J. R., R. J. Barrios, B. A. Foster, and N. M. Greenberg. 1999. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 2: 70-75.
31. Loetscher, M., T. Geiser, T. O'Reilly, R. Zwahlen, M. Baggiolini, and B. Moser. 1994. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J. Biol. Chem. 269: 232-237.
32. Carothers, A. M., G. Urlaub, J. Mucha, D. Grunberger, and L. A. Chasin. 1989. Point mutation analysis in a mammalian gene: rapid preparation of total RNA, PCR amplification of cDNA, and Taq sequencing by a novel method. BioTechniques 7: 494-499.
33. Harlow, E., and D. Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory, New York; 1988.
34. Friguet, B., A. F. Chaffotte, L. Djavadi-Ohaniance, and M. E. Goldberg. 1985. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77: 305-319.
35. Mendel, I., N. Kerlero de Rosbo, and A. Ben-Nun. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur. J. Immunol. 25: 1951-1959.
36. Karpus, W. J., and K. J. Kennedy. 1997. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukocyte Biol. 62: 681-687.
37. Rubio, N., M. M. Villacampa, N. El Hilali, and J. Blanco. 2000. Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell marker. Prostate 44: 133-143. (Pubitemid 30419188)
38. Frade, J. M., M. Mellado, G. del Real, J. C. Gutierrez-Ramos, P. Lind, and A. C. Martinez. 1997. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J. Immunol. 159: 5576-5584.
39. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
40. Moreland, L. W., G. Margolies, L. W. Heck, Jr., A. Saway, C. Blosch, R. Hanna, and W. J. Koopman. 1996. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23: 1849-1855.
41. Moreland, L. W., S. W. Baumgartner, M. H. Schiff, E. A. Tindall, R. M. Fleischmann, A. L. Weaver, R. E. Ettlinger, S. Cohen, W. J. Koopman, K. Mohler, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337: 141-147.
42. Hebert, J., D. Bernier, Y. Boutin, M. Jobin, and W. Mourad. 1990. Generation of anti-idiotypic and anti-anti-idiotypic monoclonal antibodies in the same fusion: support of Jerne's Network Theory. J. Immunol. 144: 4256-4261.
43. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner, and A. D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192: 1075-1080.
44. Haringman, J. J., D. M. Gerlag, T. J. Smeets, D. Baeten, F. van den Bosch, B. Bresnihan, F. C. Breedveld, H. J. Dinant, F. Legay, H. Gram, et al. 2006. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54: 2387-2392.
45. Strasly, M., G. Doronzo, P. Cappello, D. Valdembri, M. Arese, S. Mitola, P. Moore, G. Alessandri, M. Giovarelli, and F. Bussolino. 2004. CCL16 activates an angiogenic program in vascular endothelial cells. Blood 103: 40-49.